Feb 24 (Reuters) - Benitec Biopharma Inc BNTC.O :
* BENITEC BIOPHARMA ANNOUNCES SUCCESSFUL RESULTS FROM THE INTERIM ANALYSIS OF THE BB-301 PILOT DOSING STUDY
* BENITEC BIOPHARMA - BENITEC HAS SCHEDULED A SCIENTIFIC ADVICE MEETING IN FRANCE IN MAY 2021 TO REVIEW INTERIM DATA AND PHASE 1 CLINICAL TRIAL DESIGN
* BENITEC BIOPHARMA INC - COMPANY CONTINUES TO PLAN FOR INITIATION OF FIRST-IN-HUMAN CLINICAL STUDY OF BB-301 IN OPMD PATIENTS IN 2022